A Tale of Two Biotechs: Biogen’s Billion-Dollar Pivot and Brainstorm’s Market Crash

The biotechnology sector is experiencing a week of extreme contrasts. While major pharmaceutical players are shelling out billions to aggressively diversify their portfolios, smaller companies dedicated to complex neurological treatments are seeing their market valuations absolutely decimated.

Biogen Opens Its Wallet Biogen is paying a hefty premium to change its trajectory. The US pharma giant just announced a massive $5.6 billion all-cash buyout of Apellis Pharmaceuticals, offering $41 per share. That figure represents an 86 percent premium over the target company’s 90-day average stock price. Unsurprisingly, the market reaction was immediate and polarized. Apellis shares skyrocketed, exploding upward by 135 percent following the news. Biogen investors were a bit more cautious, sending the stock down 2.3 percent.

The deal centers around two main assets. There is Syfovre, a treatment for geographic atrophy in the eye, and Empaveli, which targets rare kidney diseases. Together, these two drugs generated $689 million in 2025. Projections show growth in the mid-to-high teens continuing until at least 2028.

Stepping Outside Neurology Historically, Biogen has built its reputation almost entirely on neurology, making a name for itself with treatments for Multiple Sclerosis and Alzheimer’s. This acquisition marks a clear departure. It brings the company’s first non-neurological products into the fold. Christopher Viehbacher, Biogen’s CEO, noted that the move immediately accelerates the company’s ongoing transformation. Snapping up Apellis expands their reach into immunology and rare diseases with two established, first-in-class medications.

Analysts Weigh the Risks Wall Street isn’t entirely sold on the details, though. Mizuho Securities took a bullish stance, suggesting the buyout finally addresses persistent investor anxiety regarding Biogen’s near and medium-term revenue growth.

Others are waving red flags. Brian Abrahams over at RBC warned that the geographic atrophy market is fiercely competitive. He pointed out that Syfovre has seen disappointing initial adoption and mixed feedback from doctors. The drug actually struggled with safety concerns back in 2023, which likely contributed to its sales dipping 4.1 percent to $586.9 million in 2025.

Then there are the Contingent Value Rights (CVRs). Apellis shareholders could get up to an extra $4 per share if Syfovre hits revenue targets of $1.5 billion to $2 billion by 2031. Joseph Stringer from Needham called the overall buyout a solid exit for Apellis, but he openly dismissed the CVR targets as unrealistic. Projecting a much lower $1.1 billion in Syfovre sales by 2031, he doesn’t expect those thresholds to be met. The whole transaction is slated to close in the second quarter of 2026, assuming regulators give it the green light.

A Bleak Picture for Brainstorm Meanwhile, the pure-play neurology space remains incredibly brutal for micro-cap developers. Brainstorm Cell Therapeutics Inc. (BCLI) is currently experiencing a devastating sell-off. The biotech firm focuses on adult stem cell therapies for severe neurodegenerative conditions like Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Progressive Multiple Sclerosis, and Parkinson’s disease.

Their proprietary NurOwn technology propagates Mesenchymal Stem Cells (MSC) and differentiates them into neurotrophic factor-secreting cells (MSC-NTF) designed for targeted transplantation at the site of damage. Despite the medical promise of offering hope to those with debilitating diseases, the financial reality is bleak. Trading on the OTC exchange, the healthcare stock closed at $1.17 before plunging a staggering 47.50 percent down to $0.63 in pre-market activity.

With a tiny market capitalization of just $6.95 million and an average trading volume of around 21,230 shares, Brainstorm is languishing near the bottom of its 52-week range of $0.46 to $1.92. While big pharma pivots to eyes and kidneys to secure immediate revenue, companies fighting in the trenches of complex neurological diseases are finding the market highly unforgiving.